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Background: Mounting evidence demonstrates a causal role for S100 proteins in tumourigenesis and several S100
isoforms have shown utility as biomarkers of several types of cancer. The S100 family is comprised of 21 small
isoforms, many of them implicated in important cellular functions such as proliferation, motility and survival.
Furthermore, in vivo experiments have proven the role of S100 proteins in tumour growth and disease progression,
while other studies have shown their prognostic value and involvement in resistance to chemotherapy drugs.
Taken together, all these aspects highlight S100 proteins as potential therapeutic targets and as a promising panel
of cancer biomarkers. In this work, we have developed a mass spectrometry (MS)-based method for the multiplexed
and specific analysis of the entire S100 protein family in tumour tissues and have applied it to investigate the
expression of S100 isoforms in the context of thyroid cancer, the main endocrine malignancy.
Methods: Selected Reaction Monitoring (SRM)-MS and stable isotope labelling/label-free analysis were employed to
investigate the expression of the 21 S100 protein isoforms in thyroid tissue samples. Specimens included 9 normal
thyroid tissues and 27 tumour tissues consisting of 9 follicular adenomas (FA), 8 follicular carcinomas (FTC) and 10
papillary carcinomas (PTC).
Results: The multiplexed and targeted mass spectrometry method led to the detection of eleven S100 protein
isoforms across all tissues. Label- and label-free analyses showed the same significant differences and results were
confirmed by western blot. S100A6, S100A11 and its putative interaction partner annexin A1 showed the highest
overexpression in PTC compared to normal thyroid. S100A13 was also elevated in PTC. Reduced S100A4 expression was
observed in FA compared to all other tissues. FA and FTC showed reduction of S100A10 and annexin A2 expression.
Conclusions: Targeted mass spectrometry allows the multiplexed and specific analysis of S100 protein isoforms in tumour
tissue specimens. It revealed S100A13 as a novel candidate PTC biomarker. Results show that S100A6, S100A11 and
Annexin A1 could help discriminate follicular and papillary tumours. The diagnostic and functional significance of S100A4
and S100A10 reduction in follicular tumours requires further investigation.
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Growing evidence links the S100 protein family with cancer
[1,2]. This protein superfamily consists of 21 small isoforms
(9-13 kDa), which are characterised by their calcium bind-
ing ability and conserved primary and secondary structures
(the sequence identity among S100 proteins ranges from 16
to 98% [3]). Besides exhibiting some degree of cell specifi-
city, S100 isoform expression depends on environmental
factors to regulate important cellular functions such as pro-
liferation and motility. When secreted from cells, some
S100 proteins exert chemotactic and angiogenic activities,
thereby further contributing to the tumourigenic process
[2,4]. Indeed, in vivo experiments have proven the role of
several S100 proteins in tumour growth and disease pro-
gression [2].
Dysregulation of S100 isoform expression has been
observed in numerous cancers [2,5] (see Additional file 1:
Table S1). For example, S100A4, S100A6, S100A8, S100A9,
S100A11 and S100P have shown altered expression in
breast, colorectal, gastric, pancreatic and prostate cancer
[6-30]. S100A6, S100A13 and S100B have been found as
overexpressed in melanoma [31-33], and likewise other
S100 proteins have been identified as biomarkers in cancer
of the bladder, lung and oesophagus [34-37]. In many in-
stances, the S100 isoforms have also demonstrated prognos-
tic and predictive value, ultimately representing candidate
therapeutic targets. For example, S100A4 elevation in colo-
rectal cancer has been associated with decreased survival
rate [6,38] and S100A4 inhibition using regulators of β-
catenin signalling such as niclosamide or sulindac has
shown reduction of liver metastasis in mouse xenograft
models [39,40]; S100A6 overexpression in gastric cancer
could serve as independent prognostic predictor associated
with poor survival [41] and S100A6 knockdown in gastric
cancer cells has been shown to inhibit tumour growth
in vivo [42]. Another S100 isoform, S100P, has been de-
scribed as a key factor in the aggressiveness of pancreatic
cancer [30] and has recently been reported as a promising
target of monoclonal antibody therapy, significantly redu-
cing tumour growth and metastasis in a mouse model [43].
Despite the promising potential of the S100 family as a
biomarker panel, there is an absence of studies that have
addressed the family-wide expression of S100 protein
isoforms in clinical samples [44]. This is a challenging
task when relying on traditional affinity-based proce-
dures (e.g. immunohistochemistry) due to potential S100
antigen cross-reactivity and the serial nature of optimis-
ing and performing IHC assay. We recently developed a
targeted mass spectrometry (MS) method based on Se-
lected Reaction Monitoring (SRM) that enables un-
equivocal structural evidence for the detection of the
entire S100 protein family in cancer cells [45]. Here, we
have adapted and extended its application for the study
of tumour tissues and demonstrate this application inthe context of thyroid cancer, the principal malignancy of
the endocrine system. The targeted MS approach allowed
us to establish the first global picture of S100 protein ex-
pression in the three most common tumours of the thyroid
gland: follicular adenoma (FA), follicular thyroid carcinoma
(FTC) and papillary thyroid carcinoma (PTC). While the
latter is the major type of thyroid cancer, tumours with fol-
licular growth pattern (FA and FTC) are indeterminate by
fine-needle aspiration (FNA) biopsy, hence hampering the
pre-operative diagnosis of tumour malignancy [46,47]. Our
results revealed isoform-specific association of S100 pro-




Fresh frozen thyroid tissues (9 normal, 9 FA, 8 minimally
invasive FTC and 10 classical PTC) were obtained from the
neuroendocrine tumour bank at the Kolling Institute of
Medical Research, Sydney. Normal samples were obtained
from dissection of non-neoplastic tissue from the contralat-
eral lobe of patients who had undergone thyroidectomy or
from patients with benign disease where thyroidectomy
was indicated. Clinicopathological features are shown in
Table 1. All PTC cases showed lymph node metastasis. The
research work was conducted with the approval of the hu-
man research ethics committees of the Northern Sydney
Local Health District (1303-091 M) and Macquarie
University (5201300037).
Metabolic (SILAC) labelling of TPC1 cells for a spike-in
standard
SILAC RPMI 1640 media (Thermo Scientific Pierce)
was supplemented with 240 mg/mL of L-arginine‐HCl
(13C6
15N4) and 40 mg/mL of L‐lysine‐2HCl (
13C6
15N2)
(Cambridge Isotope Labs), 10% dialysed FBS (Life Tech-
nologies) and 1% Penicillin-Streptomycin (Gibco). The
medium was sterile filtered through a 0.22 micron filter.
TPC1 thyroid cancer cells were cultured for at least
eight doublings at 37°C in a humidified atmosphere with
5% CO2. Upon reaching 70-90% confluence, cells were
washed with phosphate buffered saline (PBS), harvested
and stored at -80°C until use. Heavy amino acid incorp-
oration was verified by MS.
Cell and tumour sample preparation
TPC1 cells and tumour samples were suspended in lysis
buffer (20 mM HEPES, 1% sodium deoxycholate (SDOC),
0.1% SDS, 150 mM NaCl, 1 mM EDTA, pH 8) with
complete, EDTA-free protease inhibitor cocktail (Roche),
phosphatase inhibitor tablet (Thermo Scientific Pierce)
and lysed on ice with sonication (three cycles of 20 s
pulses). Lysates were centrifuged (12 000 g, 10 min,
4°C) and the supernatants retained. Protein quantitation
Table 1 Clinicopathological features of the thyroid tissue samples analysed
Normal tissues Follicular adenomas
Age Sex Age Sex Tumour size (mm)
Normal-1 42 F FA-1 36 M 30
Normal-2 20 F FA-2 51 F 15
Normal-3 78 F FA-3 30 F 30
Normal-4 61 M FA-4 46 F 50
Normal-5 51 M FA-5 46 M 30
Normal-6 34 F FA-6 14 F 8
Normal-7 84 M FA-7 21 M 21
Normal-8 35 M FA-8 68 F 8
Normal-9 29 F FA-9 59 F 10
Follicular thyroid carcinomas
Age of onset Sex Tumour size (mm) T stage Capsular invasion Vascular invasion
FTC-1 43 F 50 3 no yes
FTC-2 37 M 40 3 yes yes
FTC-3 82 M 45 3 encapsulated yes
FTC-4 16 M 13 1 yes no
FTC-5 64 F 40 2 no yes
FTC-6 64 F 25 yes (focal) no
FTC-7 20 M 110 3 no yes
FTC-8 22 M 30 2 yes yes
Papillary thyroid carcinomas
Age of onset Sex Tumour size (mm) T stage Vascular invasion Extra-thyroidal spread
PTC-1 34 F 18 2 no no
PTC-2 24 F 30 2 yes no
PTC-3 50 M 6 4 no yes
PTC-4 59 M 30 3 yes yes
PTC-5 33 F 8 1 no no
PTC-6 32 F 55 4 yes yes
PTC-7 24 F 45 3 no no
PTC-8 33 F 28 3 yes yes
PTC-9 49 M 44 3 no yes
PTC-10 56 M 55 4 yes yes
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40 ug of protein from tissue samples and 20 ug of pro-
tein from metabollically labelled TPC1 cells were mixed
in triplicate before SDS-PAGE. A ratio 2:1 of sample
protein to labelled protein was employed given that pre-
vious tests measuring the abundance of candidate refer-
ence proteins showed varying levels of actual tumour
protein amount in different samples due to the presence of
blood proteins. Labelled TPC1 cells allowed the quantitative
analysis of candidate reference proteins and S100 proteins
S100A2, S100A6, S100A10, S100A11 and S100A13. It is not
unexpected that a particular cell line does not expressdetectable levels of all S100 isoforms, therefore additional
stable isotope-labelled S100 synthetic peptides were spiked
into the samples before tryptic digestion (see below for de-
tails). While it is conceivable to perform the entire analysis
using stable isotope-labelled peptides from reference pro-
teins and S100 proteins, using the SILAC spike-in repre-
sents a less expensive approach that does not rely on prior
knowledge of the most appropriate peptide sequence to rep-
resent the target analyte.
In addition, label-free MS analysis to quantitate all
S100 proteins was also carried out as we previously de-
scribed [45]. To this end, a reference stock sample was
prepared, comprised of 700 ug of protein from TPC1
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tein pooled from the entire set of normal, FA, FTC and
PTC tumour lysates. 40 ug of this mixture was loaded
onto a Bis-Tris NuPAGE gel for separation. The set of
tissue samples was randomised and prepared in batches
of four samples (one from each tissue type as far as pos-
sible considering the different sample sizes) plus the ref-
erence sample. All samples were loaded on gels in
triplicate and processed as described below.
Corresponding aliquots of specimens and reference
samples were mixed with NuPAGE LDS sample buffer
(Invitrogen) and 50 mM dithiothreitol (DTT), incubated
at 70°C for 10 min and loaded onto 4-12% Bis-Tris
NuPAGE gels (Invitrogen). Proteins were separated
using MES running buffer (200 V, 25 min), fixed into the
gel with 50% ethanol/10% acetic acid for 1 h and then
stained for 1 h with colloidal Coomassie G-250 (Sigma).
Gel bands from three mass regions were excised (7-
14 kDa, 14-32 kDa and 32-100 kDa), cut into approxi-
mately 1 × 1 mm cubes and destained with 50% ACN in
50 mM ammonium bicarbonate (AmBic, pH 8.0). Gel
pieces were dehydrated with 100% ACN, speed-vac dried
and incubated in 10 mM DTT/100 mM Ambic at 56°C
for 1 h followed by treatment with 55 mM iodoaceta-
mide/100 mM AmBic at RT in the dark for 45 min. Gel
pieces were dehydrated again, speed-vac dried, rehy-
drated with 120 uL of 13 ng/uL trypsin solution (se-
quencing grade modified trypsin (Promega) in 50 mM
AmBic and 0.1% SDOC) and kept on ice for 1 h.
Before tryptic digestion, gel pieces from the region 7-14
kDa were spiked with 2 pmol of 13C, 15N stable-isotope la-
belled peptide standards ELPSFLGK (S100A4), ALNSIID-
VYHK (S100A8), NIETIINTFHQYSVK (S100A9) and 1
pmol of SFWELIGEAAK (S100A14) and AVIVLVENFYK
(S100A16) (SpikeTides TQL, JPT Peptide Technologies,
Germany). This step allowed the inclusion of additional
labelled S100 peptides not detected in TPC1 cells accord-
ing to preliminary tests. All samples were then incubated
overnight at 37°C. Peptides were extracted thrice with
0.1% SDOC in ultrasonic waterbath for 10 min and then
acidified with 1 uL of formic acid. The precipitate was re-
moved by centrifugation (14000 g, 10 min) and the sam-
ples were dried in a speed-vac, ready for LC-SRM-MS.
LC-SRM-MS
The selection of S100 peptides, transitions and optima
MS parameters was based on our previous work [45].
The sequences from candidate reference proteins and
putative S100 interaction partners annexin A1 (ANXA1)
and annexin A2 (ANXA2) were searched by BLAST and
Peptide Atlas to identify suitable unique tryptic peptides
with more than six amino acids and free of methionine
residues. S100 proteins to be quantitated in the tissue
samples were detected on preliminary analyses of eachsample using the list of SRM transitions reported in
Additional file 1: Table S2. These transitions were moni-
tored and also served to assign the retention times of
each peptide for subsequent time-scheduled SRM. Ac-
cording to their localisation on the gels, Table 2 lists the
peptide sequences and SRM parameters employed for
the analysis of S100 proteins and Additional file 1: Tables
S3 and S4 the candidate reference proteins in the thyroid
tissues.
Samples were analysed using a Waters nanoACQUITY
UPLC system coupled to the QTRAP 5500 mass spectrom-
eter (AB Sciex). Weak (A) and strong (B) elution solvents
were 0.1% FA (v/v) in water and 0.1% FA (v/v) in ACN, re-
spectively. Samples were loaded onto a Waters Symmetry
C18 trapping column (180 um × 20 mm, 5 um particle size)
and peptides were separated on a Waters BEH C18 nano
UPLC column (100 um × 100 mm, 1.7 um particle size) at
35°C under constant flow rate of 0.4 uL/min. Different elu-
tion gradients were used depending on the regions from
the gel: a) 7-14 kDa: 3% solvent B for 1 min, 3-40% B in
30 min and 40-85% B in 2 min, b) 14-32 kDa: 3% solvent B
for 1 min, 3-40% B in 60 min and 40-85% B in 2 min, c)
32-100 kDa: 3% solvent B for 1 min, 3-40% B in 110 min
and 40-85% B in 2 min.
Peptide samples were reconstituted with a solution of
2% ACN/0.1% TFA (v/v) and 17.8 fmol/uL of 13C15N
stable isotope-labelled peptide ESDTSYVSLK from hu-
man C-reactive protein (Auspep, Australia), used as LC
loading control for label-free experiments. Blank injec-
tions using a 30 min gradient were performed between
each sample. The lists of peptide sequences in Table 2
and Additional file 1: Tables S3 and S4 were targeted
using three transitions per peptide with corresponding
time-scheduled SRM methods employing cycle times of
1 s and transition windows of 240 s for peptides shown
in Table 2 and Additional file 1: Table S3 and 360 s for
those listed in Additional file 1: Table S4. The nano-ESI
source was operated in positive mode at 2.5 kV with
interface heater temperature of 150°C. Curtain gas was
set to 20 psi, declustering potential at 70 V and both
Q1/Q3 were set at unit resolution. Collision energies
(CE) for candidate reference peptides were calculated
based on the equations CE(2+) = 0.036*m/z + 8.857 and
CE(3+) = 0.0544*m/z-2.4099, taken from Skyline. Peptide
identities were corroborated by SRM-triggered IDA MS/
MS and searched in the UniProt human database using
Mascot v. 2.3.0.
Data analysis
The potential for peptide interferences was monitored with
AuDIT software [48] and signals marked as problematic
were removed. Data were processed with Multiquant 3.0
(AB Sciex) using the MQ4 integration algorithm. Manual
inspection of the fragment ion peaks was performed to
Table 2 Targeted S100 peptide sequences (region 7-14 kDa)
Q1 Q3 Rt Protein.peptide.transition ion.isotopologue CE CEXP
846.45 778.41 31.5 S100A1.ELLQTELSGFLDAQK.y7.light 39.3 13
846.45 865.44 31.5 S100A1.ELLQTELSGFLDAQK.y8.light 39.3 13
846.45 1208.62 31.5 S100A1.ELLQTELSGFLDAQK.y11.light 39.3 13
503.27 763.40 23.5 S100A2.ELPSFVGEK. + 2y7.light 22.7 12
503.27 666.35 23.5 S100A2.ELPSFVGEK. + 2y6.light 30.7 11
503.27 579.31 23.5 S100A2.ELPSFVGEK. + 2y5.light 30.7 9
507.27 771.41 23.5 S100A2.ELPSFVGEK. + 2y7.heavy 22.7 12
507.27 674.36 23.5 S100A2.ELPSFVGEK. + 2y6.heavy 30.7 11
507.27 587.33 23.5 S100A2.ELPSFVGEK. + 2y5.heavy 30.7 9
445.75 648.37 25.5 S100A4.ELPSFLGK. + 2y6.light 21.5 19
445.75 551.32 25.5 S100A4.ELPSFLGK. + 2y5.light 25.5 19
445.75 464.29 25.5 S100A4.ELPSFLGK. + 2y4.light 25.5 16
449.76 656.39 25.5 S100A4.ELPSFLGK. + 2y6.heavy 21.5 19
449.76 559.33 25.5 S100A4.ELPSFLGK. + 2y5.heavy 25.5 19
449.76 472.30 25.5 S100A4.ELPSFLGK. + 2y4.heavy 25.5 16
455.22 693.36 16.0 S100A4.TDEAAFQK. + 2y6.light 21.2 20
455.22 564.31 16.0 S100A4.TDEAAFQK. + 2y5.light 21.2 20
455.22 493.28 16.0 S100A4.TDEAAFQK. + 2y4.light 21.2 14
459.23 701.37 16.0 S100A4.TDEAAFQK. + 2y6.heavy 21.2 20
459.23 572.33 16.0 S100A4.TDEAAFQK. + 2y5.heavy 21.2 20
459.23 501.29 16.0 S100A4.TDEAAFQK. + 2y4.heavy 21.2 14
374.22 618.38 18.5 S100A6.ELTIGSK. + 2y6.light 20.3 13
374.22 505.30 18.5 S100A6.ELTIGSK. + 2y5.light 20.3 13
374.22 404.25 18.5 S100A6.ELTIGSK. + 2y4.light 20.3 13
378.22 626.40 18.5 S100A6.ELTIGSK. + 2y6.heavy 20.3 13
378.22 513.31 18.5 S100A6.ELTIGSK. + 2y5.heavy 20.3 13
378.22 412.26 18.5 S100A6.ELTIGSK. + 2y4.heavy 20.3 13
458.25 802.41 17.5 S100A6.LQDAEIAR. + 2y7.light 25.4 13
458.25 674.35 17.5 S100A6.LQDAEIAR. + 2y6.light 23.4 20
458.25 559.32 17.5 S100A6.LQDAEIAR. + 2y5.light 31.4 17
463.25 812.41 17.5 S100A6.LQDAEIAR. + 2y7.heavy 25.4 13
463.25 684.36 17.5 S100A6.LQDAEIAR. + 2y6.heavy 23.4 20
463.25 569.33 17.5 S100A6.LQDAEIAR. + 2y5.heavy 31.4 17
636.85 774.41 24.5 s100A8.ALNSIIDVYHK.y6.light 31.8 13
636.85 974.53 24.5 s100A8.ALNSIIDVYHK.y8.light 31.8 13
636.85 887.50 24.5 s100A8.ALNSIIDVYHK.y7.light 31.8 13
640.86 782.42 24.5 S100A8.ALNSIIDVYHK.y6.heavy 31.9 13
640.86 982.54 24.5 S100A8.ALNSIIDVYHK.y8.heavy 31.9 13
640.86 895.51 24.5 S100A8.ALNSIIDVYHK.y7.heavy 31.9 13
602.98 790.42 30.0 S100A9.NIETIINTFHQYSVK.y13.light 30.4 13
602.98 725.89 30.0 S100A9.NIETIINTFHQYSVK.y12.light 30.4 13
602.98 618.83 30.0 S100A9.NIETIINTFHQYSVK.y10.light 30.4 13
605.65 794.43 30.0 S100A9.NIETIINTFHQYSVK.y13.heavy 30.5 13
605.65 729.90 30.0 S100A9.NIETIINTFHQYSVK.y12.heavy 30.5 13
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Table 2 Targeted S100 peptide sequences (region 7-14 kDa) (Continued)
605.65 622.84 30.0 S100A9.NIETIINTFHQYSVK.y10.heavy 30.5 13
379.21 642.38 18.0 S100A10.DPLAVDK. + 2y6.light 22.5 19
379.21 545.33 18.0 S100A10.DPLAVDK. + 2y5.light 20.5 17
379.21 432.25 18.0 S100A10.DPLAVDK. + 2y4.light 20.5 17
383.22 650.40 18.0 S100A10.DPLAVDK. + 2y6.heavy 22.5 19
383.22 553.34 18.0 S100A10.DPLAVDK. + 2y5.heavy 20.5 17
383.22 440.26 18.0 S100A10.DPLAVDK. + 2y4.heavy 20.5 17
604.80 932.48 26.0 S100A10.EFPGFLENQK. + 2y8.light 26.6 13
604.80 835.43 26.0 S100A10.EFPGFLENQK. + 2y7.light 34.6 13
604.80 466.75 26.0 S100A10.EFPGFLENQK. + 2y8 + 2.light 26.6 13
608.81 940.50 26.0 S100A10.EFPGFLENQK. + 2y8.heavy 26.6 13
608.81 843.45 26.0 S100A10.EFPGFLENQK. + 2y7.heavy 34.6 13
608.81 470.75 26.0 S100A10.EFPGFLENQK. + 2y8 + 2.heavy 26.6 13
386.20 559.32 18.0 S100A11.DPGVLDR. + 2y5.light 24.2 18
386.20 502.30 18.0 S100A11.DPGVLDR. + 2y4.light 24.2 18
386.20 403.23 18.0 S100A11.DPGVLDR. + 2y3.light 20.2 18
391.21 569.33 18.0 S100A11.DPGVLDR. + 2y5.heavy 24.2 18
391.21 512.31 18.0 S100A11.DPGVLDR. + 2y4.heavy 24.2 18
391.21 413.24 18.0 S100A11.DPGVLDR. + 2y3.heavy 20.2 18
530.75 888.45 20.0 S100A11.DGYNYTLSK. + 2y7.light 24.0 14
530.75 725.38 20.0 S100A11.DGYNYTLSK. + 2y6.light 24.0 12
530.75 611.34 20.0 S100A11.DGYNYTLSK. + 2y5.light 24.0 18
534.76 896.46 20.0 S100A11.DGYNYTLSK. + 2y7.heavy 24.0 14
534.76 733.40 20.0 S100A11.DGYNYTLSK. + 2y6.heavy 24.0 12
534.76 619.35 20.0 S100A11.DGYNYTLSK. + 2y5.heavy 24.0 18
519.76 836.45 22.5 S100A13.DSLSVNEFK. + 2y7.light 23.6 13
519.76 723.37 22.5 S100A13.DSLSVNEFK. + 2y6.light 23.6 20
519.76 636.34 22.5 S100A13.DSLSVNEFK. + 2y5.light 23.6 20
523.77 844.47 22.5 S100A13.DSLSVNEFK. + 2y7.heavy 23.6 13
523.77 731.38 22.5 S100A13.DSLSVNEFK. + 2y6.heavy 23.6 20
523.77 644.35 22.5 S100A13.DSLSVNEFK. + 2y5.heavy 23.6 20
372.24 630.38 20.5 S100A13.LIGELAK. + 2y6.light 19.5 19
372.24 517.30 20.5 S100A13.LIGELAK. + 2y5.light 17.5 15
372.24 460.28 20.5 S100A13.LIGELAK. + 2y4.light 25.5 16
376.24 638.40 20.5 S100A13.LIGELAK. + 2y6.heavy 19.5 19
376.24 525.31 20.5 S100A13.LIGELAK. + 2y5.heavy 17.5 15
376.24 468.29 20.5 S100A13.LIGELAK. + 2y4.heavy 25.5 16
624.31 1047.50 20.0 S100A13.SLDVNQDSELK. + 2y9.light 31.3 16
624.31 932.47 20.0 S100A13.SLDVNQDSELK. + 2y8.light 31.3 16
624.31 833.40 20.0 S100A13.SLDVNQDSELK. + 2y7.light 31.3 14
628.32 1055.51 20.0 S100A13.SLDVNQDSELK. + 2y9.heavy 31.3 16
628.32 940.48 20.0 S100A13.SLDVNQDSELK. + 2y8.heavy 31.3 16
628.32 841.41 20.0 S100A13.SLDVNQDSELK. + 2y7.heavy 31.3 14
625.82 1016.54 31.5 S100A14.SFWELIGEAAK. + 2y9.light 29.0 17
625.82 830.46 31.5 S100A14.SFWELIGEAAK. + 2y8.light 29.0 13
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625.82 701.42 31.5 S100A14.SFWELIGEAAK. + 2y7.light 32.0 12
629.83 1024.56 31.5 S100A14.SFWELIGEAAK. + 2y9.heavy 29.0 17
629.83 838.48 31.5 S100A14.SFWELIGEAAK. + 2y8.heavy 29.0 13
629.83 709.43 31.5 S100A14.SFWELIGEAAK. + 2y7.heavy 32.0 12
647.87 912.48 31.0 S100A16.AVIVLVENFYK. + 2y7.light 28.0 14
647.87 799.40 31.0 S100A16.AVIVLVENFYK. + 2y6.light 24.0 13
647.87 700.33 31.0 S100A16.AVIVLVENFYK. + 2y5.light 26.0 12
651.88 920.50 31.0 S100A16.AVIVLVENFYK. + 2y7.heavy 28.0 14
651.88 807.41 31.0 S100A16.AVIVLVENFYK. + 2y6.heavy 24.0 13
651.88 708.34 31.0 S100A16.AVIVLVENFYK. + 2y5.heavy 26.0 12
Rt: retention time (min), CE: collision energy; CEXP: cell exit potential.
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peak areas of each endogenous peptide were summed and
divided by the transition areas of the isotopically labelled
counterparts. The calculated values of different peptides
from the same protein were averaged.
In the case of label-free analyses, co-elution of frag-
ment ions and consistency of retention times were used
as a guide for peak identity assignment. Signals with CV
less than 20% in transition ratios across samples and
replicates were considered to represent interference-
free conditions. Summed raw peak areas were first di-
vided by the total peak area of the spiked CRP peptide
and then against the peak areas of the same peptides
present in a reference pool sample that was prepared in
the same batch along with the samples of interest. This
was done to compensate for differences in sample prep-
aration and system response as detailed in [45]. Again,
the average of different peptides from the same protein
was calculated. The normalisation factors previously ob-
tained by isotopic labelling were employed for calcula-
tion of relative S100 protein expression, thereby keeping
maximum precision in this preceding step and allowing
the analysis of S100 proteins not detected in the SILAC
spike-in standard or not added as heavy peptides before
tryptic digestion.
Identification of the most stably expressed endogenous
reference proteins across all the thyroid tissue samples
(normal, FA, FTC and PTC) was performed using the
geNorm algorithm, developed by Vandesompele et al.
[49]. The geometric mean of SRM-based values of the
identified reference proteins was employed as the nor-
malisation factor to calculate the relative expression of
S100 proteins in each sample. Comparison of relative
S100 protein expression was carried out by one-way
anova and Tukey’s post hoc test (p < 0.05) using Graph-
Pad Prism 5.0 software, which was also used for linear
regressions analyses. Area under the curve (AUC) of a
receiver operating characteristic (ROC) curve was calcu-
lated using the ROCR R package.Validation of results by Western Blot
Taking into account the normalisation factors derived
from the reference proteins, 10 ug of protein from tissue
lysates of normal, FA, FTC and PTC samples were sepa-
rated on 4-12% Bis-Tris NuPAGE gels and electroblotted
onto nitrocellulose (Bio-Rad). The membrane was blocked
with 5% skim milk in TBS for 1 h at RT. For S100A4 ana-
lysis, the membrane was cut in three sections from around
5-17 kDa, 17-32 kDa and >32 kDa. The sections were in-
cubated overnight at 4°C with a) 5-17 kDa - rabbit poly-
clonal anti-S100A4 (1:100, AbCam), b) 17-32 kDa - rabbit
monoclonal anti-Rab7a (1:500, Cell signaling) and c)
rabbit monoclonal anti-β-Tubulin (1:500, Cell signaling).
For S100A13 analysis, the membrane was cut in two sec-
tions (5-17 kDa and >32 kDa) and incubated overnight
with either rabbit monoclonal anti-S100A13 (1:3000,
AbCam) or rabbit monoclonal anti-Rab7a (1:500, Cell sig-
naling). The secondary antibody was fluorescence-labelled
IRDye 800CW goat anti-rabbit IgG (H + L) (1:10 000 in
5% skim milk in TBST, LI-COR), incubated at RT for 1 h
and visualized with the Odyssey infrared imaging system.
Results
Identification of stable endogenous reference proteins in
thyroid tumours
Because tumour specimens contain naturally variable
amounts of blood proteins, and in the case of thyroid
specimens, thyroglobulin, a simple protein quantitation
assay would be insufficient for normalising loading
quantities which is a requirement for accurate quantita-
tion. Therefore, our first task was to identify endogen-
ous reference proteins within thyroid tumours that
could be used for loading normalisation. Traditionally,
‘housekeeping genes/proteins’ like GAPDH and β-actin
have been used as normalisation loading controls; how-
ever, increasing evidence shows that these may not be
the best reference proteins as their expression stability
is compromised when compared across different groups
of samples or disease states [49,50]. We used SRM to
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commonly reported as internal reference standards based
on gene expression profiling studies [50,51] (Additional
file 1: Tables S3 and S4).
In the geNorm method by Vandesompele et al. [49],
pairwise comparisons between each of the candidate pro-
teins are carried out and an expression stability value M is
calculated, which represents the average pairwise variation
across all samples of a particular protein compared with
the remaining proteins tested. In a first instance, the geN-
orm algorithm showed proteasome subunit beta type-4
(PROS26) and proteasome subunit beta type-2 (PSMB2)
as the protein pair with the highest stability, followed by
several ribosomal proteins, valosin containing protein
(VCP), Ras-related protein Rab7a and cyclophilin A. β-
Tubulin, β-Actin and GAPDH showed higher variation
(see Figure 1a). This result served to verify the consistency
of our reference protein dataset since PSMB2, PROS26,
ribosomal proteins and VCP are all involved in the
ubiquitin-proteasome system [52-55]. In order to minim-
ise the possibility of co-regulation we kept proteins be-
longing to different functional classes: Rab7a (regulator of
endo-lysosomal trafficking), cyclophilin A (regulator of
protein folding), PSMB2 (proteasome, proteolytic activity),
β-Tubulin (cytoskeletal protein), GAPDH (glycolytic pro-
tein) and protein TB2 (receptor accessory protein). We
retained and tested β-actin, another cytoskeletal protein,
given its frequent use in most expression studies.
From the selected subset, Rab7a and cyclophilin A were
the most stable proteins identified (Figure 1a) and pair-
wise variation analysis of the corresponding normalisation
factors helped to determine that Rab7a, cyclophilin A and
PSMB2 compose a minimal set of stable endogenous ref-
erence proteins in thyroid tissues (Figure 1b).a
Figure 1 Determination of reference proteins using the geNorm algo
proteins; b) Determination of the optimal number of reference proteins for
two sequential normalisation factors and stepwise inclusion of the most staDetection of S100 protein family by targeted MS
Our targeted MS assay for all members of the S100 protein
family revealed that the following eleven S100 protein iso-
forms were detected across all normal, FA, FTC and PTC
tissues: S100A1, S100A2, S100A4, S100A6, S100A8,
S100A9, S100A10, S100A11, S100A13, S100A14 and
S100A16 (Figure 2 and Additional file 1: Figure S1). The
MS assay employing the SILAC spike-in standard was highly
reproducible with median coefficient of variation (CV) of
5.8%. Although each S100 peptide has its own MS charac-
teristics, our previous work with spiking experiments of six
stable isotope-labelled peptides (ELPSFVGEK, S100A2;
ELPSFLGK, S100A4; LQDAEIAR, S100A6; DPGVLDR,
S100A11; LIGELAK, S100A13 and AVIVLVENFYK,
S100A16) demonstrated linear response with up to 3 pmol
on-column [45] and we have made broad estimates of the
limits of quantitation to be approximately 0.5 fmol (consid-
ering lowest concentration with CV <20%), which is consist-
ent with the commonly observed detection limits for
peptide SRM being in the sub-femtomolar range [56].
Targeted MS revealed S100A13 as a novel candidate
marker of PTC
As shown in Figure 2, S100A13 was found overexpressed in
tumours of PTC origin (log2fc = 1.03, p < 0.05) compared
to normal thyroid. Additionally, increased expression of
S100A13 was generally observed in FA and FTC specimens,
although this varied considerably amongst these samples.
Analysis of four publicly available gene expression datasets,
three of them comparing matched normal-PTC tumour
samples, confirmed the overexpression of S100A13 mRNA
transcripts in PTC (Additional file 1: Figure S2). The SRM-
based results were validated by Western Blot (Figure 3a)
and were highly correlated (r2 = 0.86) (Figure 3b).b
rithm. a) Average expression stability values of candidate reference
normalisation. Pairwise variations Vn/n + 1 are calculated between
ble remaining control protein.
Figure 2 Differential expression of S100 proteins in normal thyroid and tumour tissues, analysed by spike-in SILAC-SRM. Normalised
expression values were log-transformed and significant changes of S100 protein isoform expression were identified by one-way anova followed by
Tukey’s post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001). Results are expressed against the mean S100 protein expression in normal thyroid tissue
samples.
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origin
S100A4 expression was greatly decreased in benign
follicular adenomas compared with normal thyroid tis-
sue. FTCs expressed higher levels of S100A4 than FAs,
but still less than normal thyroid and PTC specimens
(Figure 2). Western Blot confirmed the quantitative MS
results of S100A4 expression in the tissue samples
(Figure 3c and d).
S100A6, S100A11 and ANXA1 are markedly
overexpressed in PTC and can discriminate tumours of
papillary and follicular histology
S100A6 and S100A11 were more abundant in PTCs com-
pared to normal thyroid (log2fc = 1.39 and log2fc = 1.44,
respectively), as previously reported [57,58]. ANXA1
is a putative S100A11 interaction partner [59] thatwe found to be highly overexpressed in PTC (log2fc =
2.25) and well correlated with S100A11 expression (r2:
0.81, Figure 3e). AUC values after ROC curve analysis
demonstrated the high discriminatory power of each of
these proteins to distinguish PTC from FA + FTC tissues
in this cohort: S100A6 AUC= 0.99, S100A11 AUC= 0.99,
ANXA1 AUC= 1.FA and FTC show reduced levels of S100A10 and ANXA2
Significantly decreased abundance of S100A10 and its
known binding partner ANXA2 [60] was shown for FA
(log2fc = - 2.47) and FTC (log2fc = -1.84) when com-
pared against normal thyroid samples. A similar result
was obtained with reference to PTC (Figure 3f ). The ex-
pression of ANXA2 and S100A10 was highly correlated
in all samples (r2: 0.93, Figure 3f ).
Figure 3 Validation of SRM-based results and correlated expression of S100 proteins with ANXA1 and ANXA2. a)Western blot of S100A13
showing overexpression in PTC tissues; b)Western Blot of S100A13 (S100A13/Rab7a, one PTC outlier excluded) showed agreement with SRM-based results;
c)Western blot of S100A4, β-tubulin and Rab7a in thyroid tumours and normal thyroid . β-tubulin presented higher variation (CV = 46%) than Rab7a
(CV = 19%); d) Normalised S100A4 expression (S100A4/Rab7a) was well correlated with that from SRM analysis. e) Expression of S100A11 and its interaction
partner ANXA1 are highly correlated across all samples, and are overexpressed in PTC; f) Expression of S100A10 and its interaction partner ANXA2 are also
highly correlated across all samples, and are both reduced in FA and FTC.
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No significant expression differences were observed for
S100A1, S100A2, S100A8, S100A9, S100A14 and S100A16
in FA, FTC and PTC specimens with respect to normal thy-
roid tissue, except for S100A2 and S100A8 in FA. S100A8
and S100A9 are known to form heterodimers and their co-
ordinated expression was observed in all tissues examined
(Additional file 1: Figure S3).
Results based on label-free SRM of S100 proteins
The analysis of S100 proteins by label-free SRM provided
essentially the same results as those found by stable-isotope
labelling (see Figure 4 and Additional file 1: Figure S4). The
median CV was higher, 19.9%, which is in line with the re-
sults obtained in the analysis of cell lines in our previous
work [45] and with other studies by label-free SRM using a
spiked standard [61]. S100A1 was not detected in the TPC1
cell line used for SILAC spike-in quantitation and it was
analysed using the label-free approach only. Figure 5 shows
that label-free SRM analyses are also well correlated with
Western blot results, as in the case of SRM with stable-
isotope labelling (Figure 3b and d)
Discussion
The S100 protein family represents a promising panel of
biomarkers for cancer and other diseases. However,
methods are lacking for the quantitative screening of
multiple S100 protein isoforms in clinical specimens.
Here, we have showed that targeted MS using SRM en-
ables the specific and multiplexed quantitation of S100
proteins in a large-scale study with 37 tissues of thyroid
origin. As our method provided relative quantitation be-
tween samples it was necessary to investigate which
proteins in thyroid tissues could act as stable endogen-
ous reference proteins, which in this case were Rab7a,a
Figure 4 Label-free analysis of S100 proteins is well correlated with labelli
label-free SRM data of S100 proteins in thyroid tissues (relative values aga
values.cyclophilin A and PSMB2. To the best of our know-
ledge, this is the first study to identify these loading
control proteins for thyroid cancer specimens. Of note,
others have already detected dysregulation of β-actin
and tubulin isoforms in FA, FTC and PTC [62], hence
supporting our strategy. Additionally, Western blot cor-
roborated the variation in expression levels of β-tubulin
and Rab7a across different tissue samples (CV of 46%
vs. 19%, respectively, Figure 3c).
The MS method harnesses the high accuracy and pre-
cision of SILAC-based MS quantitation and expands the
number of targeted S100 protein isoforms through the
use of label-free SRM. Although the quantitation with
the SILAC spike-in achieved greater precision than the
label-free experiments, both approaches identified the
same significant changes in the tissue samples and were
well correlated. Isotope-labelled peptide standards offer
an advantage in that LC retention time and non-specific
peptide interferences can be readily determined. More-
over, the SRM technique can readily be configured to
measure protein concentration through the inclusion of
quantified stable isotope peptide standards [63]. While
we have determined the appropriate normalisation fac-
tors for relative quantitation of S100 proteins in thyroid
samples, to extend this to other cancer types we recom-
mend using the SILAC spike-in standard to establish
these factors. The full accompaniment of S100 proteins
can then be quantitated by label-free SRM of SDS-
PAGE fractionated samples, which we have shown to be
an effective approach to minimise sample matrix back-
ground [45].
Our experiments revealed the novel observation of in-
creased S100A13 in PTC compared with FA, FTC and
normal thyroid tissue, and this was supported by West-
ern blot and previous studies of mRNA transcript levels.b
ng-based quantitation: a) Global comparison between label-based and
inst normal tissues); b) Comparison removing two upper extreme
Figure 5 Comparison of label-free SRM and Western blot analysis of S100A4 and S100A13. (S100A4, r2 0.93; S100A13, r2 0.80).
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observed to decrease the invasive potential in vitro [64].
Moreover, S100A13 is known to participate in a multi-
protein complex that facilitates the release of fibroblast
growth factor 1 (FGF-1) [65]. Increased FGF-1 expression
has been previously observed in differentiated thyroid can-
cer (DTC) [66]. Binding of secreted FGFs with heparan
sulphate proteoglycans enables signalling through receptor
tyrosine kinases to activate MAPK and PI3K/AKT path-
ways which contribute to tumour growth and angiogenesis
[67]. Interestingly, S100A13 upregulation has recently been
linked to resistance to the chemotherapeutic agents dacar-
bazine or temozolomide in melanoma patients [68]. Others
have shown S100A13 to be an angiogenic marker [32].
Extrapolating these findings to thyroid cancer implicates
S100A13 as a new oncogenic factor in PTC, and this
could warrant evaluation of the effectiveness of inhibit-
ing S100A13-driven release of FGF-1.
Overexpression of S100A6 in PTC has been observed
previously [57], but more studies are needed to under-
stand its functional significance. S100A11 has recently
been shown to reduce the loss of contact inhibition,
anchorage-independent growth and resistance to anoi-
kis in PTC cells and enhance the activity of PTC-
associated oncogenes such as BRAFV600E and TRK-T3
[58]. We have shown that S100A11 expression is con-
sistent among normal and follicular histotypes, despite
being elevated in PTC. The MS method demonstrated
that S100A6, S100A11 and ANXA1 differentiate PTC
from follicular tumours and that ANXA1 is highly cor-
related with S100A11 expression. While not directly
analysed here, the utility of our findings could be ex-
plored for distinguishing the follicular variant of PTC.
FA and FTC cannot be readily distinguished by cytologic
evaluation of FNA biopsies, which poses an important diag-
nostic issue. Our findings using the MS assay show the loss
of S100A4 in follicular adenoma tissue compared with fol-
licular thyroid carcinoma, so this difference in expression
has diagnostic potential. A previous study did not report the
decrease of S100A4 in FA [69]. Our result might be ex-
plained by considering that tumour tissue analysis by MSallows the inclusion of both cancer and stromal S100A4-
positive cells, which are known to cooperate to drive
tumour progression and metastasis [70]. Since S100A4 has
well-established pro-migratory, invasive and angiogenic ac-
tivities [71], it would be of interest to examine S100A4 ex-
pression in metastatic radioactive iodine-refractory DTC,
where it could emerge as a possible therapeutic target. A
proof of concept has already been demonstrated in a mouse
model with anaplastic thyroid carcinoma, showing absence
of metastasis in mice inoculated with S100A4-shRNA
knockdown cells [72].
The reduced expression of S100A10 in FA and FTC was
well correlated with the expression of its interaction partner
ANXA2. The S100A10-ANXA2 complex anchors to the
plasma membrane via the ANXA2 subunits and has an ac-
tive role in the trafficking of ion channels [60]. A previous
IHC study showed only low S100A10 immunoreactivity in
PTC tissues while essentially all normal, FA and FTC sam-
ples were S100A10-negative [73]. Our results show clearly
higher levels of S100A10-ANXA2 in normal tissues
compared with FA and FTC. Whether or not loss of
S100A10 in the tumour microenvironment exerts a
functional role in follicular thyroid neoplasia is a subject
of future investigations.
Conclusions
We have demonstrated the use of targeted mass spectrom-
etry for the multiplexed and specific analysis of S100 pro-
tein isoforms in thyroid tumour specimens. This approach
provides unambiguous structural evidence of S100 protein
isoform expression thereby overcoming potential problems
of antigen cross-reactivity that can interfere with affinity
detection methods. This study led to the global character-
isation of S100 protein expression in thyroid tumours and
highlighted several S100 protein isoforms for potential diag-
nostic and therapeutic evaluation. S100A13 emerged as a
novel candidate PTC biomarker. Our results indicate that
S100A6, S100A11 and ANXA1 have utility to discriminate
follicular and papillary thyroid tumours. The diagnostic and
functional significance of S100A4 and S100A10 reduction
in follicular tumours warrants further investigations.
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Additional file 1: Table S1. Types of cancer where the altered
expression of S100 proteins/genes has been observed. For more details,
readers are encouraged to consult the reviews [1-5] and literature
focused on each S100 protein/cancer. Table S2. List of precursors (Q1)
and fragment ions (Q3) for detection of S100 peptides. CE: Collision
energy, CEXP: Cell exit potential. Table S3. Targeted peptide sequences
of candidate reference proteins in the region 14-32 kDa. Table S4.
Targeted peptide sequences of candidate reference proteins in the
region 32-100 kDa. Figure S1. Expression of S100 proteins S100A1,
S100A14 and S100A16 in normal and tumour thyroid tissues as analysed
by the MS assay. Normalised expression values (against reference
proteins) were log-transformed and significant changes of S100 protein
expression were identified by one-way anova followed by Tukey’s post
hoc test. Results are expressed against the mean S100 protein expression
in normal tissue samples; *p<0.05, **p<0.01, ***p<0.001. Figure S2.
S100A13 mRNA expression in matched normal-tumour samples from
GEO Series a) GSE3467 b) GSE33630 and c) GSE3678. Samples in d)
GSE9115 are not matched. Groups were analysed by unpaired (GSE9115)
or paired t test (matched samples); *p<0.05, **p<0.01, ***p<0.001.
Figure S3. S100A8 and S100A9 expression showed good correlation in
the normal and tumour tissues. The graph was plotted with log2 values
of SRM-based normalised S100 protein expression. Figure S4. Relative
expression of S100 proteins in thyroid tissues according to label-free SRM
data Figure S4. (cont). Relative expression of S100 proteins in thyroid
tissues according to label-free SRM data.
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